Stay updated with breaking news from Marc semigran. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Edgewise Therapeutics, Inc., , a leading muscle disease biopharmaceutical company, today announced the dosing of the first patient in the Phase 2 CIRRUS-HCM trial of EDG-7500. EDG-7500 is a novel. ....
Marc Semigran is a cardiologist and chief medical officer of a biotechnology company developing cardiac gene therapy.He shares his story and discusses his KevinMD article, "It’s time to start approaching heart disease like breast cancer." ....
Form 425 Renovacor, Inc. Filed by: Renovacor, Inc. streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Published: Jun 03, 2021 By Alex Keown 180 Life Sciences Russell T. Ray and Teresa DeLuca were appointed to the board of directors of 180 Life Sciences. Ray was formerly Managing Director and co-Head of Global Health Care at Credit Suisse First Boston Corporation. More recently, Ray was a Partner and Senior Advisor to HLM Venture Partners, a health care-focused venture capital firm. He currently serves on the board of directors of Merrimack Pharmaceuticals, Inc. DeLuca comes to 180 Life Sciences as both a public independent board director and former senior executive Chief Medical Officer. Her most recent role was at Columbia University as Managing Director of NY Life Science Venture Fund. ....